Predicine Recognized Among Global Top 5 Liquid Biopsy Innovators in Oncology

At the beginning of 2021, StartUs Insights, a data science company headquartered in Europe, released its list of the “Top 5 Global Liquid Biopsy Innovators Impacting Oncology.” Predicine (Huidu Medical) was recognized as a global pioneer in technological innovation for its next-generation DNA+RNA liquid biopsy technology.

Over the past six months, Huidu Medical’s breakthrough achievements in liquid biopsy have garnered extensive attention from healthcare sectors both domestically and internationally. The company was successively included in CB Insights’ lists of “China’s 41 Most Promising Molecular Diagnostics Companies” and “28 Chinese Companies Leading Cancer Liquid Biopsy,” and was ranked among China’s “Top 50 Unicorns in the New Healthcare Industry 2020.” Leveraging technological innovation, international branding, and commercial potential, Huidu Medical has distinguished itself in the field of liquid biopsy.

For this selection, StartUs Insights analyzed over 1,116,000 innovative companies, evaluating technological innovators based on artificial intelligence and data recognition. Taking into account factors such as geographic location, founding date, and technological advantages, the firm conducted a multi-tiered assessment of 55 liquid biopsy companies worldwide, ultimately selecting five companies with the greatest commercial promise in clinical oncology, including Huidu Medical.

These five innovative companies’ proprietary technologies represent the industry’s top tier in their respective fields. Huidu Medical has pioneered the industry’s first efficient, ultra-sensitive RNA+DNA “Gene Radar” next-generation liquid biopsy technology and algorithmic models with independent intellectual property rights. It has established a closed-loop genetic testing system and smart medical data platform based on blood, urine, and tumor tissues. Leveraging core technologies such as artificial intelligence and machine learning, Huidu Medical leads the international liquid biopsy sector, with widespread applications in guiding clinical medication, monitoring recurrence, and early cancer screening. The other four innovative companies and their respective technologies are: Mursla’s NPQuantumSense exosome quantum sensing technology (UK), Lucence’s AmpliMARK amplicon-based ctDNA sequencing technology (Singapore), SmartCatch’s CTC capture technology (France), and GENECAST’s Allele-Discriminating Priming System (South Korea).

As an international leader in the precision medicine industry, Huidu Medical adheres to the professional standard of “starting at the pinnacle of the industry” to create premium industry solutions. Building on its foundations with European and American pharmaceutical companies, Huidu Medical has developed internationally leading next-generation liquid biopsy technologies, global solutions for precision clinical trials, and a network of CAP- and CLIA-certified laboratories operating synchronously in China and the United States. By engaging in deep collaborations with top-tier global pharmaceutical companies ranked among the top ten worldwide, as well as with leading domestic and international experts and medical institutions, Huidu Medical supports global new drug clinical trials, companion diagnostic development, and early cancer screening through its one-stop biomarker platform system based on blood, urine, and tissue samples.

StartUs Insights is a global data science company headquartered in Austria. Its platform covers more than 1,379,000 innovative and high-growth companies worldwide. By delivering rapid, comprehensive solutions and high-quality technical resources, it has earned widespread acclaim from global customers, helping them easily identify potential leads and create direct value.